Arcturus Therape Stock Price, News & Analysis

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in two upcoming investor conferences. The SVB Securities Global Biopharma Conference will take place on February 15, 2023 at 2:20 p.m. ET, followed by the Barclays Global Healthcare Conference on March 16, 2023 at 9:00 a.m. ET. Arcturus is focused on developing messenger RNA medicines, including vaccines for infectious diseases and therapies for rare liver and respiratory diseases. Additional details and webcast links are available on their website.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced the approval of its Clinical Trial Application (CTA) for ARCT-032, an inhaled mRNA treatment for cystic fibrosis (CF). This marks the progression into Phase 1 First-in-Human studies in New Zealand. Joseph Payne, CEO, emphasized the potential of ARCT-032 to restore CFTR protein in CF patients, including those without effective treatment options. Preclinical data showcased robust CFTR expression in human bronchial epithelial cells. Cystic fibrosis, a serious genetic disorder, currently lacks effective treatments for many mutation types, making this development particularly significant.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in the Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2023, at 9:00 a.m. Pacific Time. The company, known for its mRNA medicines and vaccines, will discuss its pipeline focused on vaccines for infectious diseases and treatments for rare liver and respiratory diseases. A webcast of the presentation will be available on the company's investor relations website.

Founded in 2013, Arcturus continues to innovate in RNA therapeutics with extensive patent coverage.

Arcturus Therapeutics, a late-stage clinical mRNA medicines company, has appointed John Markels, Ph.D., to its Board of Directors. With over 35 years of industry experience, including as President of Global Vaccines at Merck, Dr. Markels will provide strategic oversight for the company's vaccine franchise and manufacturing processes. This appointment is expected to enhance Arcturus' efforts in developing novel self-amplifying mRNA vaccines in collaboration with CSL Seqirus, positioning the company for greater innovation in infectious disease vaccines.

Arcturus Therapeutics (Nasdaq: ARCT) announced a global partnership with CSL for developing self-amplifying mRNA vaccines, securing $200 million upfront and up to $4.3 billion in potential milestones. BARDA awarded $63.2 million for mRNA vaccine development targeting pandemic influenza. Recent data show the effectiveness of ARCT-032 in restoring chloride ion current in cystic fibrosis patients. For Q3 2022, Arcturus reported revenues of $13.4 million, a substantial increase from $2.4 million in Q3 2021, but a net loss of $35.3 million. Cash reserves stood at $237.7 million as of September 30, 2022.

Scholar Rock (NASDAQ: SRRK) appointed Dr. Jing L. Marantz as Chief Medical Officer, bringing over 20 years of experience in neurology, hematology/oncology, and rare diseases. Dr. Marantz, previously of Krystal Biotech, will oversee clinical development including the Phase 1 DRAGON trial for SRK-181 and Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy (SMA). CEO Jay Backstrom noted her expertise will enhance the company’s innovative approach to targeting TGFβ growth factors.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in two upcoming investor conferences. The Company will host a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, at 2:45 p.m. ET, and present at the 34th Annual Piper Sandler Healthcare Conference on November 29, 2022, at 11:30 a.m. ET. Arcturus focuses on developing mRNA medicines targeting infectious diseases and rare liver and respiratory conditions.

An agreement between Arcturus Therapeutics (NASDAQ: ARCT) and CSL Seqirus has been announced, positioning Arcturus for a potential financial boon. The collaboration includes an upfront payment of $200 million and potential total payments exceeding $4 billion for development and commercialization milestones. Arcturus will hold a 40% profit sharing for COVID-19 vaccines and receive double-digit royalties on flu and other respiratory vaccines. This partnership leverages Arcturus’ self-amplifying mRNA technology and CSL's extensive manufacturing capabilities.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced it will release its financial results for Q3 2022 after market close on November 9, 2022. A conference call and webcast will follow at 4:30 PM EST. The company focuses on developing mRNA medicines for infectious diseases and rare liver and respiratory diseases. Arcturus' pipeline includes candidates for COVID-19, Influenza, and various genetic disorders. Founded in 2013 and based in San Diego, it employs innovative technologies like LUNAR® lipid-mediated delivery and STARR™ mRNA Technology.